17:53 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Spyryx's SPX-101 improves lung function in Phase II CF trial

Spyryx Biosciences Inc. (Durham, N.C.) said high-dose SPX-101 given via a portable nebulizer led to a placebo-adjusted increase in percent predicted forced expiratory volume in 1 second (ppFEV1) from baseline to day 28 of 5.2%...
21:40 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Spyryx starts Phase II for CF

Spyryx Biosciences Inc. (Durham, N.C.) began a Phase II trial evaluating SPX-101 in up to 78 patients with cystic fibrosis. The placebo-controlled, Canadian and European trial will evaluate 2 dose levels of twice-daily inhaled SPX-101...
01:40 , May 5, 2017 |  BC Week In Review  |  Clinical News

Spyryx reports positive Ph I safety data for SPX-101

In February, Spyryx Biosciences Inc. (Durham, N.C.) reported that single and multiple ascending doses of inhaled SPX-101 for 14 days were well tolerated and led to no dose-limiting toxicities (DLTs) in a Phase I trial...
20:58 , Nov 11, 2016 |  BC Week In Review  |  Clinical News

SPX-101: Preclinical data

In a mouse model of CF, SPX-101 significantly improved survival at day 14 vs. vehicle-treated controls (p=0.04). SPX-101 also significantly improved mucociliary clearance vs. controls (p<0.05). Data were presented at the North American Cystic Fibrosis...
07:00 , Aug 3, 2015 |  BioCentury  |  Emerging Company Profile

Going SPLUNCing

Spyryx Biosciences Inc. is developing inhaled peptides for cystic fibrosis that inhibit the sodium channel responsible for regulating fluid volume in the lungs. The peptides could offer a pan-genotypic treatment that is more efficacious than...
02:17 , May 8, 2015 |  BC Extra  |  Financial News

Spyryx raises $18M in series A

Respiratory newco Spyryx Biosciences Inc. (Research Triangle Park, N.C.) raised $18 million in a series A round from Canaan Partners; Hatteras Venture Partners; and 5AM Ventures. The University of North Carolina spinout is developing preclinical...
08:00 , Feb 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BPI fold containing family A member 1 (BPIFA1; LUNX)

Cancer INDICATION: Non-small cell lung cancer (NSCLC) In vitro, mouse and patient sample studies suggest anti-BPIFA1 antibodies could help treat NSCLC. In patient samples, BPIFA1 levels were higher in primary NSCLC tumors and metastases than...